The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
31-Jul-08
$10.3 billion
Target:
TransAlta Corporation
Acquiror:
LS Power Equity Partners / Global Infrastructure Partners
Advised TransAlta Corporation, a power generation and wholesale marketing company, on an unsolicited offer from LS Power Equity Partners / Global Infrastructure Partners
11-Oct-22
Pending
$7.9 billion
Target:
Westinghouse Electric Company
Acquiror:
Brookfield Renewable Partners and Cameco
Advising the Independent Committee of Brookfield Renewable Partners, the flagship listed renewable power company of Brookfield Asset Management, in consortium with Cameco and other institutional partners, on the acquisition of Westinghouse Electric Company, one of the world’s largest nuclear services businesses, from Brookfield Business Partners
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
29-May-18
$3.5 billion
Target:
Trans Mountain Pipeline system, Trans Mountain Expansion Project and related pipeline and terminal assets
Acquiror:
Government of Canada
Advised the Government of Canada on the acquisition of the Trans Mountain Pipeline system, the Trans Mountain Expansion Project and related pipeline and terminal assets from Kinder Morgan Canada Limited
20-Jun-11
$2.0 billion
Target:
Capital Power Income L.P.
Acquiror:
Atlantic Power Corporation
Advised Capital Power Income L.P., a Canadian power trust with a portfolio of 20 power generation assets located in Canada and the United States (total net generating capacity of 1,400 MW), on its sale to Atlantic Power Corporation
07-Jun-09
$1.6 billion
Target:
EPCOR Power L.P.
Advised the Independent Committee of the Board of Directors of EPCOR Power L.P., an Alberta-based power trust, on approval of the transfer of its GP interest and 30.6% LP interest from EPCOR Utilities to a newly formed company, Capital Power Corporation
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
19-Dec-19
$770 million
Target:
Wireless Infrastructure Group Limited
Acquiror:
Brookfield Asset Management
Advised 3i Infrastructure plc on the sale of Wireless Infrastructure Group Limited, a leading independent telecommunications infrastructure provider focusing on mobile towers and indoor connectivity
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
08-Jun-15
$45 million
Target:
Aralez Pharmaceuticals Inc.
Acquiror:
QLT Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
06-May-11
$NA
Target:
Aker Solutions (Aker Holding)
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to its investment in Aker Holding, the largest shareholder of Aker Solutions during the demerger of the company’s EPC activities
20-Dec-12
$NA
Target:
Germanischer Lloyd
Acquiror:
Det Norske Veritas
Advised Det Norske Veritas on its merger with Germanischer Lloyd to create the third largest player in the Testing, Inspection and Certification industry, focused on ship classification, oil & gas and energy
05-Feb-14
$NA
Target:
Unfors Raysafe AB
Acquiror:
Fluke Biomedical Corporation
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin